Q32 BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.22 USD | +0.85% |
|
-12.89% | +137.57% |
| May. 21 | Leerink Partners Starts Q32 Bio With Outperform Rating | MT |
| May. 09 | Q32 Bio Inc. Provides Corporate Update | CI |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 310.5 | - | - |
| Enterprise Value (EV) 1 | 404.3 | 586.4 | 489.8 |
| P/E ratio | -6.76 x | -5.93 x | -5.25 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | -7.83 x | -9.57 x | -6.87 x |
| FCF Yield | -12.8% | -10.4% | -14.6% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 11,942 | - | - |
| Reference price 2 | 26.00 | 26.00 | 26.00 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -53.07 | -57.96 | -66.53 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -36.54 | -56.24 | -66 |
| Net income 1 | -53.74 | -35.56 | -62.8 | -80.2 |
| Net margin | - | - | - | - |
| EPS 2 | -7.410 | -3.845 | -4.387 | -4.953 |
| Free Cash Flow 1 | - | -51.61 | -61.26 | -71.31 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -14.84 | -12.74 | -12.74 | -12.74 | -14.22 | -14.22 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 1.205 | -12.58 | -12.58 | -12.58 | -14.06 | -14.06 |
| Net income 1 | 1.029 | -11.63 | -12.1 | -12.65 | -14.06 | -14.06 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | 1.030 | -0.9733 | -1.013 | -1.050 | -0.8200 | -0.8200 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | 93.8 | 276 | 179 |
| Net Cash position 1 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -51.6 | -61.3 | -71.3 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 2.67 | 2.81 | 3.42 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
26
USD
Average target price
49.67
USD
Spread / Average Target
+91.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +137.57% | 310M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -0.47% | 22.1B | |
| -9.28% | 18.34B | |
| -41.70% | 16.59B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- QTTB Stock
- Financials Q32 Bio Inc.
